WallStSmart

CME Group Inc (CME)vsValue Line Inc (VALU)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CME Group Inc generates 19837% more annual revenue ($6.74B vs $33.83M). VALU leads profitability with a 65.0% profit margin vs 63.3%. VALU trades at a lower P/E of 14.6x. CME earns a higher WallStSmart Score of 65/100 (C+).

CME

Buy

65

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 4.3Quality: 5.0
Piotroski: 2/9Altman Z: 0.30

VALU

Hold

44

out of 100

Grade: D

Growth: 3.3Profit: 7.0Value: 6.0Quality: 9.0
Piotroski: 4/9Altman Z: 3.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CME6 strengths · Avg: 9.0/10
Profit MarginProfitability
63.3%10/10

Keeps 63 of every $100 in revenue as profit

Operating MarginProfitability
69.8%10/10

Strong operational efficiency at 69.8%

Market CapQuality
$90.52B9/10

Large-cap with strong market position

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
21.3%8/10

Earnings expanding 21.3% YoY

Free Cash FlowQuality
$1.24B8/10

Generating 1.2B in free cash flow

VALU6 strengths · Avg: 9.2/10
Profit MarginProfitability
65.0%10/10

Keeps 65 of every $100 in revenue as profit

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.2810/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
20.4%9/10

Every $100 of equity generates 20 in profit

P/E RatioValuation
14.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

CME3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
4.522/10

Expensive relative to growth rate

Altman Z-ScoreHealth
0.302/10

Distress zone — elevated risk

VALU2 concerns · Avg: 2.5/10
Market CapQuality
$319.73M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-7.7%2/10

Revenue declined 7.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : CME

The strongest argument for CME centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 63.3% and operating margin at 69.8%. Revenue growth of 14.4% demonstrates continued momentum.

Bull Case : VALU

The strongest argument for VALU centers on Profit Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 65.0% and operating margin at 12.1%.

Bear Case : CME

The primary concerns for CME are Piotroski F-Score, PEG Ratio, Altman Z-Score.

Bear Case : VALU

The primary concerns for VALU are Market Cap, Revenue Growth.

Key Dynamics to Monitor

CME profiles as a mature stock while VALU is a declining play — different risk/reward profiles.

VALU carries more volatility with a beta of 1.07 — expect wider price swings.

CME is growing revenue faster at 14.4% — sustainability is the question.

CME generates stronger free cash flow (1.2B), providing more financial flexibility.

Bottom Line

CME scores higher overall (65/100 vs 44/100), backed by strong 63.3% margins and 14.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CME Group Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

CME Group Inc. (Chicago Mercantile Exchange, Chicago Board of Trade, New York Mercantile Exchange, The Commodity Exchange) is an American global markets company. It is the world's largest financial derivatives exchange, and trades in asset classes that include agricultural products, currencies, energy, interest rates, metals, stock indexes and cryptocurrencies futures.

Visit Website →

Value Line Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

Value Line, Inc. produces and sells investment periodicals and related publications primarily in the United States. The company is headquartered in New York, New York.

Visit Website →

Want to dig deeper into these stocks?